By Andrea: http://nursingoncologyjob.com
Neogenix Oncology, Inc. recently announced that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.
Neogenix has developed an ELISA serum biomarker using, NPC-1C, its novel, proprietary chimeric antibody that selectively targets pancreatic and colorectal cancer. The prospective study, being conducted at Conemaugh Cancer Center, in Johnstown, PA, provides for the evaluation of blood serum samples from patients confirmed with pancreatic or colon cancer. Preliminary results demonstrate the Neogenix biomarker assay’s ability to differentiate between blood serum of healthy donors and that of patients with colorectal or pancreatic cancer. In addition, the results of the NPC-1C biomarker test indicate superior sensitivity as compared to commercially available CEA and CA19-9 assays. A complete data set will be presented at the ASCO Meeting.
"We are very excited about the study results which hold promise for the early detection of these devastating diseases. These tests could provide a real hope for patients by enabling early intervention and substantially improved clinical outcome,” says Philip M. Arlen, M.D, President and CEO of Neogenix Oncology.
Showing posts with label oncology. Show all posts
Showing posts with label oncology. Show all posts
Saturday, October 16, 2010
Friday, October 8, 2010
Pfizer: Oncology Research Update
By Andrea: http://www.nursingoncologyjob.com
Pfizer (PFE) Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers. These results will be presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12.
"Pfizer (NYSE: PFE) has focused its oncology research on targeting molecular drivers and pathways in various cancers, such as EGFR, ALK and IGF-1R," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We are committed to using this approach to seek treatments for well-known, difficult-to-treat and rare tumor types that have few or no therapeutic options and where we can make a big impact in defined patient populations."
At ESMO, Pfizer will present data on key compounds from its portfolio, which includes:
* PF-00299804
Updated results from a global, randomized Phase 2 trial evaluating the anti-tumor activity and safety of PF-00299804 compared to erlotinib in patients with NSCLC following progression on treatment with one or more chemotherapy regimens (Abstract #365PD, October 10).(1) In addition, preliminary efficacy and safety data from a Phase 2 study evaluating PF-00299804 as first-line treatment in patients with advanced NSCLC whose tumors are likely to carry the EGFR mutation will be presented as a late breaker in a Proffered Paper session (Abstract #LBA18, October 11).(2)
PF-00299804 is an investigational, oral, pan-HER (pan-human epidermal growth factor receptor) inhibitor.(2) PF-00299804 is currently being evaluated in the BR.26 clinical trial, a Phase 3, double-blind, placebo-controlled, randomized study in patients with stage IIIB/IV NSCLC who have progressive disease following standard chemotherapy and EGFR inhibitor therapy.(3) BR.26 is led by the NCIC Clinical Trials Group (CTG).(3)
* Crizotinib (PF-02341066)
Updated data on crizotinib (PF-02341066), a first-in-class, oral ALK inhibitor, will also be presented, from the ongoing expansion cohort from the Phase 1 study evaluating the compound in patients with ALK-positive advanced NSCLC (Abstract #366PD, October 10).(4)
* Sunitinib
Pfizer will also present results from SUN 1087, a Phase 3 trial evaluating sunitinib plus erlotinib compared to erlotinib alone in patients with advanced NSCLC who have received at least one previous treatment with a platinum-based regimen (Abstract #LBA6, October 11).(5) In August, Pfizer announced that this study demonstrated a statistically significant improvement in progression-free survival but not in overall survival. Overall survival was the primary endpoint of the study and progression free survival was the secondary endpoint of the study.
Pfizer will also present progression-free survival (PFS) data as determined by blinded independent central review (BICR) from the pivotal, placebo-controlled SUN 1111 Phase 3 trial evaluating sunitinib in patients with progressive, well-differentiated pancreatic neuroendocrine tumor (NET) (Abstract #747P, October 9).(6)
* Figitumumab
Results from a Phase 1/2 study evaluating figitumumab (CP-751,871), a selective fully human IgG2 monoclonal antibody against the IGF-1R (insulin-like growth factor 1 receptor) pathway, in patients with refractory Ewing's sarcoma and other sarcomas will be presented in a Proffered Paper session (Abstract #1344O, October 10).(7)
Pfizer continues to investigate approved therapies within its portfolio, including Aromasin® (exemestane tablets). At the Congress, research findings for the compound will be presented in two key presentations.
- Distant recurrences at median of 5-years among 9,779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy (Abstract #213O, October 11)(8)
- Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis (Abstract #225P, October 10)(9)
Data on the following compounds and investigational agents will also be presented: neratinib (HER2 positive breast, solid tumors),(10),(11) axitinib (renal cell carcinoma or RCC),(12) inotuzumab (non-Hodgkin's lymphoma),(13) and Torisel® (temsirolimus) (RCC, solid tumors).(14),(15)
Pfizer (PFE) Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers. These results will be presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12.
"Pfizer (NYSE: PFE) has focused its oncology research on targeting molecular drivers and pathways in various cancers, such as EGFR, ALK and IGF-1R," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "We are committed to using this approach to seek treatments for well-known, difficult-to-treat and rare tumor types that have few or no therapeutic options and where we can make a big impact in defined patient populations."
At ESMO, Pfizer will present data on key compounds from its portfolio, which includes:
* PF-00299804
Updated results from a global, randomized Phase 2 trial evaluating the anti-tumor activity and safety of PF-00299804 compared to erlotinib in patients with NSCLC following progression on treatment with one or more chemotherapy regimens (Abstract #365PD, October 10).(1) In addition, preliminary efficacy and safety data from a Phase 2 study evaluating PF-00299804 as first-line treatment in patients with advanced NSCLC whose tumors are likely to carry the EGFR mutation will be presented as a late breaker in a Proffered Paper session (Abstract #LBA18, October 11).(2)
PF-00299804 is an investigational, oral, pan-HER (pan-human epidermal growth factor receptor) inhibitor.(2) PF-00299804 is currently being evaluated in the BR.26 clinical trial, a Phase 3, double-blind, placebo-controlled, randomized study in patients with stage IIIB/IV NSCLC who have progressive disease following standard chemotherapy and EGFR inhibitor therapy.(3) BR.26 is led by the NCIC Clinical Trials Group (CTG).(3)
* Crizotinib (PF-02341066)
Updated data on crizotinib (PF-02341066), a first-in-class, oral ALK inhibitor, will also be presented, from the ongoing expansion cohort from the Phase 1 study evaluating the compound in patients with ALK-positive advanced NSCLC (Abstract #366PD, October 10).(4)
* Sunitinib
Pfizer will also present results from SUN 1087, a Phase 3 trial evaluating sunitinib plus erlotinib compared to erlotinib alone in patients with advanced NSCLC who have received at least one previous treatment with a platinum-based regimen (Abstract #LBA6, October 11).(5) In August, Pfizer announced that this study demonstrated a statistically significant improvement in progression-free survival but not in overall survival. Overall survival was the primary endpoint of the study and progression free survival was the secondary endpoint of the study.
Pfizer will also present progression-free survival (PFS) data as determined by blinded independent central review (BICR) from the pivotal, placebo-controlled SUN 1111 Phase 3 trial evaluating sunitinib in patients with progressive, well-differentiated pancreatic neuroendocrine tumor (NET) (Abstract #747P, October 9).(6)
* Figitumumab
Results from a Phase 1/2 study evaluating figitumumab (CP-751,871), a selective fully human IgG2 monoclonal antibody against the IGF-1R (insulin-like growth factor 1 receptor) pathway, in patients with refractory Ewing's sarcoma and other sarcomas will be presented in a Proffered Paper session (Abstract #1344O, October 10).(7)
Pfizer continues to investigate approved therapies within its portfolio, including Aromasin® (exemestane tablets). At the Congress, research findings for the compound will be presented in two key presentations.
- Distant recurrences at median of 5-years among 9,779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy (Abstract #213O, October 11)(8)
- Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis (Abstract #225P, October 10)(9)
Data on the following compounds and investigational agents will also be presented: neratinib (HER2 positive breast, solid tumors),(10),(11) axitinib (renal cell carcinoma or RCC),(12) inotuzumab (non-Hodgkin's lymphoma),(13) and Torisel® (temsirolimus) (RCC, solid tumors).(14),(15)
Subscribe to:
Posts (Atom)
